Stepan Company

Stepan Company (SCL) Market Cap

Stepan Company has a market capitalization of $1.16B.

Price: $51.28

β–Ό -0.27 (-0.52%)

Market Cap: 1.16B

NYSE Β· time unavailable

CEO: Luis E. Rojo

Sector: Basic Materials

Industry: Chemicals - Specialty

IPO Date: 1992-03-17

Website: https://www.stepan.com

Stepan Company (SCL) - Company Information

Market Cap: 1.16B|Sector: Basic Materials

Company Profile

Stepan Company, together with its subsidiaries, produces and sells specialty and intermediate chemicals to other manufacturers for use in various end products. It operates through three segments: Surfactants, Polymers, and Specialty Products. The Surfactants segment offers surfactants that are used as principal ingredients in consumer and industrial cleaning products, including detergents for washing clothes, dishes, carpets, and floors and walls, as well as shampoos and body washes; and other applications, such as fabric softeners, germicidal quaternary compounds, disinfectants, and lubricating ingredients. Its surfactants are also used in various applications, including emulsifiers for spreading agricultural products; and industrial applications comprising latex systems, plastics, and composites. The Polymers segment provides polyurethane polyols that are used in the manufacture of rigid foam for thermal insulation in the construction industry, as well as a base raw material for coatings, adhesives, sealants, and elastomers (CASE); polyester resins, including liquid and powdered products, which are used in CASE applications; and phthalic anhydride that is used in unsaturated polyester resins, alkyd resins, and plasticizers for applications in construction materials, as well as components of automotive, boating, and other consumer products. The Specialty Products segment offers flavors, emulsifiers, and solubilizers for use in food, flavoring, nutritional supplement, and pharmaceutical applications. It serves in the United States, France, Poland, the United Kingdom, Brazil, Mexico, and internationally. Stepan Company was founded in 1932 and is headquartered in Northbrook, Illinois.

Analyst Sentiment

92%
Strong Buy

From 1 Active Polls

1Y Forecast: $75.00

β–² +46.3% Potential Upside

Consensus Target Metrics

Low Bound

$75

Median

$75

High Bound

$75

Average

$75

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$75.00
β–² +46.26% Upside
Low Target
$75.00
46% Risk
Median Target
$75.00
46% Mid
High Target
$75.00
46% Max
Consensus
Buy
3 / 3 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

πŸ“Š Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)1,1651,1441,0841,0911,2481,2621,4781,7641,889
Enterprise Value ($M)1,7371,7161,6421,6801,8821,8852,0612,3612,492
Price to Earnings Ratio (P/E)-82.53-6.9154.1325.1627.5116.00110.2818.6849.61
Price/Earnings-to-Growth Ratio (PEG)β€”-0.76β€”β€”113.821.24β€”β€”54.86
Price to Sales Ratio (P/S)0.501.891.961.852.102.132.813.233.40
Price to Book Ratio (P/B)0.980.960.870.871.011.051.261.451.58
Price to Free Cash Flow Ratio (P/FCF)-60.49-81.98-34.8427.13-86.64-48.8846.0621.36-9083.61
Enterprise Value to Sales (EV/Sales)β€”2.842.962.853.163.183.924.324.48
Enterprise Value to EBITDA (EV/EBITDA)8.4635.1632.3129.9638.0132.6157.9145.0452.92
Debt to Equity Ratio2.790.600.560.570.580.610.580.610.61

⚑ SCL Growth Runway Model

Standard long term linear growth fade

Multi-Stage Discounted Cash Flow Sandbox

Market Price$51.28
Intrinsic Value$0.00
Market Alignment
Overvalued by 143.0%relative to calculated intrinsic value
9.00%
Exp: 1%1%
i

Growth runway slowdown

This value provides a time window for the growth rate to decline beyond Stage 1 toward the terminal rate. Longer windows are most useful for companies with high growth starting conditions or strong competitive advantages. This option stretches out the growth rate slowdown across 5, 10, or 15-year steps. A high-growth starting condition (exceeding a 25% initial growth rate) automatically applies a curve decay to simulate realistic, rapid market saturation.
i

Terminal growth rate

With long-term inflation between 3-5%, revenue must grow by that baseline to maintain flat real-world market share. This value sets the permanent terminal growth rate to factor into the valuation beyond the growth slowdown runway toward maturity.

3-Stage Financial Runway Horizon

🧠 Perpetuity Horizon Engine (Stage 3: Post-2035)

Terminal FCF Base$0.00B
Perpetuity TV Value$0.07B
Discounted TV (PV)$0.03B
TV Weighting %57.6%
⚠️
Financial Model Disclaimer & Risk Disclosure: This interactive scenario simulator is an educational sandbox provided strictly for informational and analytical research purposes. Core historical financial statements and consensus estimates are sourced directly via Financial Modeling Prep (FMP). All downstream outputs are entirely deterministic, hypothetical projections generated by combining automated mathematical formulas (including linear interpolation and Gaussian bell-curve decay models) with user-selected variables and third-party financial data inputs. Users assume all liability for trading decisions executed based on these sandbox calculations.

πŸ“˜ Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

πŸ“˜ STEPAN (SCL) β€” Investment Overview

🧩 Business Model Overview

STEPAN is a specialty chemicals manufacturer focused on surfactants and surface-active formulations used across personal care, home care/detergents, and industrial applications, along with polyurethane-related products and other formulated chemical specialties. The value chain typically starts with commodity-derived and other industrial feedstocks, which are processed into intermediate chemistries (e.g., surface-active agents and polyurethane building blocks). These inputs are then converted into higher-performance products tailored to customer formulations, such as wetting, emulsifying, cleaning, dispersion, and foam-control solutions.

Revenue is driven by the ability to supply consistent performance at industrial scale, supported by technical application support and formulation know-how. Customer stickiness is enhanced because many products are qualified through formulation trials, regulatory/quality documentation, and performance benchmarking, creating practical barriers to switching suppliers.

πŸ’° Revenue Streams & Monetisation Model

STEPAN monetizes through a portfolio of industrial and performance chemical products where margins are influenced by the spread between input costs and finished-product pricing, plus the mix of higher-value specialties versus more commoditized outputs. The model is not β€œpurely recurring” in a software sense; however, the company can exhibit repeat purchase behavior due to qualified supply, long-term customer relationships, and ongoing demand from end-market production cycles.

  • Product-driven revenue: Surfactant and specialty chemical sales tied to customer production volumes in cleaning, personal care, coatings, and related industrial segments.
  • Margin drivers: (1) operational efficiency and asset utilization, (2) specialty mix (performance-based products generally carry better pricing power than basic intermediates), and (3) raw-material pass-through versus lagged pricing/contracting.
  • Application value: Pricing reflects performance attributes (e.g., stability, compatibility, end-use efficiency), not only chemical composition. This supports healthier margins when demand shifts toward formulation-level solutions.

🧠 Competitive Advantages & Market Positioning

The core moat is a combination of high customer switching costs and process/scale competence, with performance differentiation that matters at the formulation level.

  • Switching costs / qualification moat: Customers often qualify surfactant systems through technical trials, documentation, and performance testing in their specific processes (pH/temperature tolerance, stability, foam characteristics, skin/hair compatibility for personal care, and regulatory expectations for end products). This makes supplier changes operationally costly and time-consuming.
  • Operational and know-how advantages: Surfactants and polyurethane intermediates are sensitive to manufacturing quality, consistency, and impurity profiles. Maintaining yield, specifications, and reliability can be difficult to replicate quickly by smaller entrants.
  • Portfolio breadth: Cross-application coverage can help balance end-market seasonality and support customer β€œsolution” offerings rather than single-commodity substitution.

Competitive benchmarking (primary peers):

  • Croda (CDR) β€” stronger emphasis on consumer-facing and specialty ingredients, with broader lifestyle/personal care exposure.
  • Evonik (EVK) β€” diversified specialty chemicals with extensive additive and performance materials portfolios, including surfactant-adjacent offerings.
  • Huntsman β€” more prominent in polyurethanes and related industrial materials, competing in polyurethane-linked chemical solutions.

Positioning contrast: While peers may be more diversified across end markets and product classes, STEPAN’s competitive stance is anchored in surface-active and polyurethane-related performance chemistry where qualification and formulation integration favor established suppliers with reliable manufacturing and technical application support.

πŸš€ Multi-Year Growth Drivers

  • Demand resilience in cleaning and hygiene: Elevated structural demand for hygiene and cleaning products supports underlying consumption of surfactant systems in developed and emerging markets.
  • Formulation complexity and performance upgrades: Regulatory and consumer requirements drive shifts toward products that perform under specific conditions (water hardness, temperature ranges, mildness targets, and stability). This favors suppliers with application engineering capabilities.
  • Polyurethane and industrial coatings ecosystem: Polyurethane-related products feed coatings, foams, and specialty industrial applications. Product adoption is tied to material performance improvements and end-use durability/efficiency.
  • Supply reliability and qualification-driven share retention: Specialty chemical markets can exhibit β€œstickiness” once plants and formulations are qualified. A differentiated supplier can defend share through performance and continuity rather than pricing alone.
  • Operational excellence and mix management: Over a 5–10 year horizon, improvements in asset reliability, specialty mix, and manufacturing efficiency can compound results even without major end-market surprises.

⚠ Risk Factors to Monitor

  • Commodity feedstock volatility: Input costs for industrial chemicals and derived feedstocks can swing, and margins depend on the speed and extent of pricing response.
  • End-market cyclicality: Surfactant demand is influenced by consumer/home-care cycles and industrial activity (coatings, lubricants, and related uses), creating earnings variability around macro conditions.
  • Environmental, regulatory, and compliance costs: Specialty chemicals face evolving environmental standards (emissions, wastewater, hazardous handling). Compliance and capital requirements can be significant.
  • Operational execution risk: Plant outages, yield issues, and supply disruptions can impair shipments and margin structure. Specialty chemical customers typically value reliability, so disruptions can have outsized impact.
  • Customer concentration and contract terms: Large customers can negotiate pricing and contract structures; adverse terms or reduced volumes can pressure profitability.

πŸ“Š Valuation & Market View

Specialty chemicals are often valued using EV/EBITDA and earnings power frameworks, with multiples reflecting both (1) normalized margins and (2) perceived durability of specialty mix and customer qualification. Because earnings can be sensitive to commodity spreads and utilization, valuation typically re-rates when the market gains confidence in:

  • Margin sustainability (specialty mix and cost discipline)
  • Consistency of demand (less exposure to pure commoditization)
  • Operational reliability (stable output, fewer disruptions)
  • Effective pricing-to-cost dynamics (ability to manage spread volatility)

Ultimately, investors look for evidence that high-performance products and qualified customer relationships can offset cyclical end-market pressure.

πŸ” Investment Takeaway

STEPAN presents an evergreen specialty-chemicals thesis centered on formulation-driven switching costs, manufacturing reliability, and performance differentiation in surfactants and polyurethane-related specialties. The investment case is strengthened when specialty mix and operational execution stabilize margin structure against commodity volatility, enabling the company to compound earnings power through qualified customer relationships and end-market demand for high-performance cleaning and industrial chemical solutions.


⚠ AI-generated β€” informational only. Validate using filings before investing.

πŸ“° Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for SCL.

seekingalpha.comβ€’2026-06-05

Dividend Champion, Contender, And Challenger Highlights: Week Of June 7

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.

gurufocus.comβ€’2026-05-01

Stepan Co (SCL) Stock Up 3.1% and Still Undervalued -- GF Score: 77/100

On May 01, 2026, Stepan Co (SCL) shares rose 3.1% to a current price of $51.59. This move comes amid a 52-week trading range that has seen a high of $68.00 and

seekingalpha.comβ€’2026-04-28

Stepan Company (SCL) Q1 2026 Earnings Call Transcript

Stepan Company (SCL) Q1 2026 Earnings Call Transcript

zacks.comβ€’2026-04-28

Stepan Co. (SCL) Beats Q1 Earnings Estimates

Stepan Co. (SCL) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.21 per share. This compares to earnings of $0.84 per share a year ago.

prnewswire.comβ€’2026-04-28

Stepan Declares Quarterly Dividend

NORTHBROOK, Ill., April 28, 2026 /PRNewswire/ -- Stepan Company (NYSE:SCL) today reported: The Board of Directors of Stepan Company has declared a quarterly cash dividend on the Company's common stock of $0.395 per share.

prnewswire.comβ€’2026-04-28

Stepan Reports First Quarter 2026 Results

NORTHBROOK, Ill., April 28, 2026 /PRNewswire/ --Β Stepan Company (NYSE: SCL) today reported: First Quarter 2026 Highlights Reported net income was a $41.4 million loss versus $19.7 million of income in the prior year.

zacks.comβ€’2026-04-21

Earnings Preview: Stepan Co. (SCL) Q1 Earnings Expected to Decline

Stepan Co. (SCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

prnewswire.comβ€’2026-04-07

Stepan to Announce First Quarter 2026 Results on April 28, 2026

NORTHBROOK, Ill., April 7, 2026 /PRNewswire/ -- Stepan Company (NYSE: SCL) will issue its first quarter 2026 earnings results on Tuesday, April 28, 2026 at approximately 7:00 a.m.

defenseworld.netβ€’2026-04-05

SG Americas Securities LLC Boosts Stake in Stepan Company $SCL

SG Americas Securities LLC grew its holdings in shares of Stepan Company (NYSE: SCL) by 166.8% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 46,410 shares of the basic materials company's stock after buying an additional 29,017 shares during the quarter. SG

seekingalpha.comβ€’2026-03-28

Stepan Company: The Ride Higher Isn't Over Yet

Stepan Company (SCL) is reaffirmed as a 'buy' due to compelling valuation and significant cost-saving initiatives. SCL's Project Catalyst targets $100M in pre-tax savings over two years, with 60% expected in the current year. Despite mixed profitability and cash flow, SCL remains attractively priced versus peers, especially on cash flow metrics.

seekingalpha.comβ€’2026-02-25

Stepan Company: Upside Unclear, Better Alternatives Exist

Stepan Company remains a 'BUY' with a lowered fair value estimate of $85/share and a price target of $71/share, reflecting increased market uncertainty. SCL's 2025 results show early signs of operational recoveryβ€”6% EBITDA growth, reduced net debt, and positive FCF in 4Q25β€”driven by asset rationalization and cost savings. 2026E forecasts nearly double AEPS versus 2025, with 47% growth expected, but much of this upside appears priced in after the recent share price surge.

247wallst.comβ€’2026-02-24

3 Dividend Kings That Have Raised Payouts for 50+ Years and Still Look Cheap

Dividend King stocks are surprisingly cheap across the board because most investors are still heavily leaning on growth stocks.

defenseworld.netβ€’2026-02-24

Stepan (NYSE:SCL) Shares Gap Down After Earnings Miss

Stepan Company (NYSE: SCL - Get Free Report)'s stock price gapped down before the market opened on Monday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $67.23, but opened at $60.98. Stepan shares last traded at $55.9680, with a volume of 36,093 shares. The basic materials company reported ($0.02)

seekingalpha.comβ€’2026-02-23

Stepan Company (SCL) Q4 2025 Earnings Call Transcript

Stepan Company (SCL) Q4 2025 Earnings Call Transcript

zacks.comβ€’2026-02-23

Stepan Co. (SCL) Reports Q4 Loss, Misses Revenue Estimates

Stepan Co. (SCL) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of $0.35. This compares to earnings of $0.12 per share a year ago.

πŸ“Š AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"SCL reported Q1’26 revenue of $604.5M and net income of -$41.4M (EPS -$1.81). Compared with Q4’25, revenue rose to $604.5M from $553.9M (+9.2% QoQ), but profitability deteriorated materially as net income swung from +$5.0M to -$41.4M. On a YoY basis, revenue in Q1’26 was slightly higher than Q1’25 ($604.5M vs. $593.3M, +1.9% YoY), while net income fell sharply (-$41.4M vs. +$19.7M, down ~-310%). Over the four-quarter trend, margins clearly contracted: gross margin declined to ~10.7% from ~12.7% in Q1’25, and net margin moved from +3.3% (Q1’25) to -6.8% (Q1’26). Cash flow also weakened versus prior periods. Operating cash flow was +$16.9M in Q1’26, down from +$59.99M in Q4’25, and free cash flow was +$16.9M (capex shown as zero in the cash flow line item). The company continues to pay dividends (about -$9.0M) but with negative earnings, dividend coverage is pressured. Balance sheet resilience is mixed: total assets were $2.33B and equity increased to ~$1.19B, while leverage remains meaningful with net debt of ~$525M. On total shareholder returns, the stock price is $51.42 with only +9.5% 1Y momentum, so returns appear more value/defensive than high-momentum."

Revenue Growth

Neutral

Revenue improved QoQ (+9.2% to $604.5M) but was only modestly up YoY (+1.9% vs. $593.3M).

Profitability

Neutral

Net income swung from +$5.0M (Q4’25) to -$41.4M (Q1’26) and fell from +$19.7M YoY (down ~310%). Net margin contracted to -6.8% from +3.3% (Q1’25).

Cash Flow Quality

Neutral

Operating cash flow fell to +$16.9M from +$60.0M QoQ and earnings are negative. Dividends were still paid (~-$9.0M), so cash/earnings coverage looks weaker.

Leverage & Balance Sheet

Fair

Assets were stable near $2.33B; equity rose to ~$1.19B. Net debt increased to ~$525M, indicating leverage remains a watch item but the balance sheet does not show collapse.

Shareholder Returns

Caution

1Y price change is +9.47% (no >20% momentum). Dividend yield is ~0.8%, so total return support is limited given current negative earnings.

Analyst Sentiment & Valuation

Caution

Street target consensus is $75 vs. current ~$51.42 (implied upside), but profitability deterioration reduces confidence in near-term fundamentals.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Stepan’s Q1 2026 results were pressured by Surfactants volatility and one-time restructuring, but the underlying portfolio mix shows resilience. Reported performance deteriorated sharply (net loss of $-41.4M; adjusted EPS down 47% YoY), driven mainly by lower Surfactant absorption and Asia production timing differences, competitive pressure in Mexico, a U.S. cold snap, and elevated oleochemical inputs. Management repeatedly framed several P&L effects as temporary/onetime and expects recoveryβ€”at least partialβ€”particularly as pricing stickiness improves (CNO/PKO alignment) and as timing normalizes into Q2. Polymers delivered +8% adjusted EBITDA growth, supported by North America Spray Foam and commodity Phthalic Anhydride volume, partially offset by weaker Europe construction demand. Specialty Products grew strongly (+30% volume in MCT), though EBITDA is lagging raw material costs. Liquidity remains a focus: free cash flow was negative (-$14M), with net debt $511M and leverage 2.7x. Project Catalyst remains on track for ~$100M pretax savings, with the majority expected to begin in Q2, alongside a Pasadena utilization ramp toward ~80% in 2026.

AI IconGrowth Catalysts

  • Surfactants: Organic net sales up 8% with +2% organic volume, led by Crop Productivity, Industrial Cleaning, Oilfield; double-digit growth in Tier 2/Tier 3 and all regions except Asia
  • Specialty Products: Volume up 30% driven by continued growth in the MCT product line
  • Polymers: Adjusted EBITDA up 8% YoY driven by 5% North America volume growth (Spray Foam and commodity Phthalic Anhydride) and global margin improvement
  • Pasadena, Texas ramp-up: Expect ~80% utilization on average in 2026 and full utilization in 2027 to drive supply chain savings and future volume growth

Business Development

  • Entered agreement to sell nonproductive assets, especially land at the Millsdale site for $30 million; expected close in fall 2026 after due diligence/regulatory steps
  • Pricing/pass-through: reliance on pass-through contracts for higher raw material costs (oil-supply-chain related), used to support selling prices

AI IconFinancial Highlights

  • Reported net loss: $-41.4M (-$1.81 diluted EPS) vs prior-year net income $19.7M ($0.86 diluted EPS)
  • Adjusted net income: $10.3M ($0.45 diluted EPS), down 47% YoY vs $19.3M ($0.84 diluted EPS)
  • Adjusted EBITDA: $49.6M, down 14% YoY ($57.5M prior year), mainly Surfactants down due to lower absorption/production timing in Asia, competitive pressure in Mexico, U.S. cold snap, and elevated oleochemical input costs
  • Surfactants adjusted EBITDA: down $7M (-15% YoY); management expects at least partial recovery in future quarters (timing/onetime)
  • Polymers adjusted EBITDA: up 8% YoY despite lower net sales (-11%); improved North America performance from Spray Foam/Phthalic Anhydride and global margin improvement
  • Specialty Products: net sales +24% YoY to $21M with volume +30%; adjusted EBITDA slightly down due to product mix and lag in raw material prices (expected to recover later)
  • Income statement restructuring impact: $65.4M pretax ($51.2M after tax) charge tied to Hillsborough NJ closure and decommissioning selected assets (cash impact < $1M in the quarter)
  • Cash flow: Cash from operations $17M; free cash flow -$14M due to typical first-quarter working capital build
  • Balance sheet: net debt $511M; leverage 2.7x (lower than Q1 2025)
  • Tax/income: mention of favorable effective tax rate partly offsetting pretax decline (no numeric tax-rate change disclosed)

AI IconCapital Funding

  • Dividends: $8.9M paid in the quarter; Board declared quarterly cash dividend of $0.395/share (58th consecutive year dividend increase)
  • CapEx: $31M in Q1 2026
  • CapEx guidance/range (2026): $105M to $115M (midpoint ~$100M referenced by analyst); sustaining/base reliability/infrastructure ~75%-80% of total
  • No buyback disclosed in the transcript
  • Deleveraging focus: reiterated objective to deleverage in 2026 while generating positive free cash flow

AI IconStrategy & Ops

  • Project Catalyst: comprehensive asset-footprint and operating-model transformation; expected ~$100M pretax savings over 2 years with ~60% expected in 2026
  • Project Catalyst execution: closed Hillsborough, NJ site and decommissioned selected assets at Millsdale (IL) and Stalybridge (UK) during late March/early April
  • Quarterly savings cadence: management expects majority of Catalyst savings to ramp in Q2 vs Q1 because footprint decisions were executed at end of March/beginning of April
  • Asset monetization: selling Millsdale nonproductive land for $30M, targeted close fall 2026
  • Surfactants operational headwind characterization: lower absorption and production timing issues in Asia (plus U.S. cold snap) described as temporary/onetime with recovery expected in future quarters

AI IconMarket Outlook

  • Project Catalyst: β€œon track” to deliver committed savings in 2026; majority of 2026 savings expected to start in Q2
  • Pasadena utilization: ~80% utilization on average in 2026 and full utilization in 2027

AI IconRisks & Headwinds

  • Iran war / Persian Gulf escalation: raw material inflation increasing; pricing generally supported by pass-through contracts, but raw material availability remains a challenge with shortages in some supply chains
  • Competitive pressure in Mexico: cited as a driver of Surfactants EBITDA decline
  • Production/timing volatility: lower absorption and production timing differences in Asia; U.S. cold snap described as impacting Q1 results
  • Oleochemical raw material cost pressure still working through P&L; management expects improved margin as pricing relationships stabilize
  • Asia Surfactants volume/absorption impacts described as potentially recoverable; extent of recovery depends on timing
  • European Polymers construction market weakness: double-digit decline in Europe due to macro uncertainty and depressed construction demand

Q&A: Analyst Interest

  • Iran war impacts (raw materials, pricing, shortages): Management said raw material inflation is escalating but pass-through contracts and disciplined price increases are working in most businesses; however, some supply chains are heavily impacted and shortages can limit growth. They emphasized supplier coordination to secure a β€œfair share” while continuing growth efforts.
  • Surfactants margin pressure trajectory: Management characterized Q1 Surfactants issues (lower absorption and production timing) as temporary/onetime and noncash; they cited a $7M (-15%) EBITDA reduction and expected at least partial recovery (at least half) in subsequent quarters. They also referenced CNO vs PKO dynamics improving pricing stickiness into Q2 and beyond.
  • Project Catalyst savings cadence and timing: Management clarified that Catalyst footprint decisions were executed at end of March/beginning of April, so most savings should appear starting in Q2 rather than being linear from Q1. They reiterated the 60% 2026 savings target, with some offsetting inflation while the majority ramps now.

Sentiment: MIXED

Note: This summary was synthesized by AI from the SCL Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

πŸ“‹ Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for SCL.

SEC EDGAR Live Feed
Loading financial data and tables...
πŸ“

SEC Filings (SCL)

Β© 2026 Stock Market Info β€” Stepan Company (SCL) Financial Profile